Literature DB >> 8591779

Bacteremia and sepsis.

K L Ferguson1, L Brown.   

Abstract

Recent evolution in the thinking of sepsis syndrome has provided a framework on which new clinical and basic research can be built. The separation of the inciting event and the cascade of subsequent physiologic changes has profound effects on how sepsis is thought of and ultimately how it will be treated. Early identification and treatment of infections and identifying patients at risk, to prevent SIRS, is the current role of Eps. Resuscitation of severe sepsis is more complex than other forms of shock and may require extensive resources if rapid admission or transfer to an intensive care unit is not available. As in many instances, the EP must be knowledgeable and skilled in the early identification and initial management of these patients until the definitive care can be provided. Modulation of the inflammatory response appears to be a prime prospect, but its practicality remains to be proved. Research and future roles of EPs include defining the population of ED patients at risk for SIRS and use of mediators of the inflammatory response. Emergency medicine is positioned in a critical point in the care of these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8591779     DOI: 10.1016/s0733-8627(05)70244-3

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  2 in total

1.  A novel heart rate variability based risk prediction model for septic patients presenting to the emergency department.

Authors:  Mas'uud Ibnu Samsudin; Nan Liu; Sumanth Madhusudan Prabhakar; Shu-Ling Chong; Weng Kit Lye; Zhi Xiong Koh; Dagang Guo; R Rajesh; Andrew Fu Wah Ho; Marcus Eng Hock Ong
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

2.  Validation of Rapid Antimicrobial Susceptibility Testing directly from blood cultures using WASPLab®, including Colibrí and Radian® in-Line Carousel.

Authors:  Pauline Hilda Herroelen; Robbe Heestermans; Kristof Emmerechts; Kristof Vandoorslaer; Ingrid Wybo; Denis Piérard; Astrid Muyldermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-02-25       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.